Slide 1: Doug Ingram, President and CEO, Sarepta Therapeutics
Doug Ingram President and CEO Sarepta Therapeutics, Inc. (NASDAQ: SRPT) June 22, 2023 Exhibit 99.1
Slide 2: Forward-looking statements
This presentation contains “forward-looking statements.” Any statements that are not statements of historical fact may be deemed to be forward-looking statements. Words such as “believe,” “anticipate,” “plan,” “expect,” “will,” “may,” “intend,” “prepare,” “look,” “potential,” “possible” and similar
Slide 3: Elevidys (delandistrogene moxeparvovec-rok)
Elevidys delandistrogene moxeparvovec-rok| Suspension for intravenous infusion
Slide 4: An Historic Milestone In Genetic Medicine
An Historic Milestone In Genetic Medicine BENJAMIN Living with Duchenne muscular dystrophy ©Sarepta therapeutics, inc. 2023. All rights reserved. 4
Slide 5: Disease progression in Duchenne
Disease progression in Duchenne1-3 Bushby K, Finkel R, Birnkrant DJ, et al. Lancet Neurol. 2010;9:77-93. Emery AEH. Lancet. 2002;359:687-695. Landfeldt E, Lindgren P, Bell CF, et al. Neurology. 2014;83(6):529-536. EARLY AMBULATORY 5 TO 7 YEARS Motor delay Enlarged calves Toe walking Standing from su
Slide 6: Sarepta is the recognized leader in Duchenne research and commercialization
Sarepta is the recognized leader in Duchenne research and commercialization….
Slide 7: The Patient Journey
The Patient Journey
Slide 8: PMO patient journey
PMO patient journey Consult Authorize Coordinate Infuse Diagnose Prescribe Confirm DMD diagnosis based on genotyping test Discuss with DMD Expert MD writes prescription and submits Enrollment form First infusion Initiate access/reimbursement effort i.e. Identify prior authorization criteria Determin
Slide 9: Gene therapy patient journey is more complex
Gene therapy patient journey... …is more complex and requires engaging a multitude of stakeholders along the way Consult Screen Refer Authorize Coordinate Infuse Monitor Diagnose Follow up Prescribe Procure Reimburse Confirm DMD diagnosis based on genotyping test Discuss treatment options, including
Slide 10: Assessing the value of delandistrogene moxeparvovec (SRP-9001)
Journal of Market Access and Health Policy Assessing the value of delandistrogene moxeparvovec (SRP-9001) gene therapy in patients with Duchenne muscular dystrophy in the United States
Slide 11: A holistic approach to assessing innovative treatments
Health Benefits Net costs Productivity Value of knowing Fear of Contagion Severity of disease Value of hope Real- option value VALUE Caregiver Impact Equity Scientific spillover A holistic approach to assessing innovative treatments Applicable to Duchenne Further discussion on applicability to Duche
Slide 12: Cost-effectiveness analysis shows value of ELEVIDYS
The cost-effectiveness analysis shows the value of ELEVIDYS in treating Duchenne cost-effective in a range of $5 million to $13 million compared to standard-of-care alone ELEVIDYS has the potential to be…
Slide 13: ELEVIDYS price below cost-effectiveness range
The cost-effectiveness analysis shows the value of ELEVIDYS in treating Duchenne cost-effective in a range of $5 million to $13 million compared to standard-of-care alone ELEVIDYS has the potential to be… At a price of $3.2 million ELEVIDYS is below the cost-effectiveness range
Slide 14: Expanding the Label
Expanding the Label
Slide 15: Reaching More Patients
Reaching More Patients
Slide 16: Thank You
Thank You ©Sarepta therapeutics, inc. 2023. All rights reserved. 16
Slide 17: Q&A
Q&A
Slide 18: Doug Ingram, President and CEO, Sarepta Therapeutics
Doug Ingram President and CEO Sarepta Therapeutics, Inc. (NASDAQ: SRPT) June 22, 2023